Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

Abstract

Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

“…The multidimensional burden of disease in North American and European AD patients is well documented. Relative to the general population, patients with AD experience increased levels of itch, pain, sleep disturbance, anxiety and depression, as well as an impaired health‐related quality of life (HRQoL) 11, 12, 13, 14, 15. In contrast, published data on the burden of AD in the Japanese patient population is limited to two relatively small studies 16, 17…”

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

“…3,4 In patients with moderate-to-severe atopic dermatitis, skin lesions can encompass a large bodysurface area and are frequently accompanied by intense, persistent pruritus, which leads to sleep deprivation, symptoms of anxiety or depression, and a poor quality of life. [5][6][7] For patients with moderate-to-severe atopic dermatitis, topical therapies have limited efficacy, and systemic treatments are associated with substantial toxic effects. Thus, there is an unmet need for effective and safe long-term medications for these patients.…”

Compliance Difficulties in Atopic Children, Reflections from an Eczema School in Sweden

“…The examples above are cases typical for the patient group that tends to need help over a prolonged period of time. We know that of patients with atopic dermatitis the majority of the patients symptoms disappear in early teens [22,23] but for those with more severe atopic dermatitis many will have ongoing clinical symptoms also as adults [24][25][26] and it is important that clinical, social or cultural reasons for frequent relapses are considered.…”

“…Case 4 illustrates the importance to always, when problems with compliance are suspected, re-evaluate the diagnosis. One important differential diagnosis when treatment seems inadequate is of course contact allergy to the local treatment used, tixocortol pivalate as such is not found in dermatological preparations but it is a marker for hydrocortisone allergy [26].…”